Glioblastoma (GBM) is the most malignant subtype of glioma and the methylation status of the Methylguanine-DNA Methyltransferase (MGMT) was proven to be a crucial factor to select the most appropriate therapy, which is currently assessed through brain biopsy. This evidence concerns the gene MGMT and glioblastoma.